Replies to post #144477 on Elite Pharmaceuticals Inc (ELTP)

[dr_lowenstein]

Nice due diligence, is it not?

nah, old news. Look at this:

There was no difference in change in UPDRS among dosages. The most common adverse events were peripheral edema (30) and dizziness (24). Isradipine 10 mg daily was the maximal tolerable dosage in this study of early PD. A large placebo-controlled trial will be necessary and is planned to assess efficacy of isradipine 10 mg daily to slow progression of PD disability.

http://www.ncbi.nlm.nih.gov/pubmed/24123224


no difference in UPDRS